Dr. Reddy’s Laboratories RDY and China-based Bio-Thera Solutions announced that they have entered into commercialization and license agreements for BAT2206, a proposed biosimilar of Johnson & ...

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Bimekizumab – an IL-17A and IL-17F inhibitor – outdid both placebo and IL-12/IL-23 blocker Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic ...

The report noted that J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which J&J ...

This approval for Crohn’s disease may make Tremfya a direct competitor with Stelara. Perspective from Edward V. Loftus Jr., MD The FDA has approved Tremfya as the “first and only ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...

BAT2206, the proposed biosimilar to J&J’s Stelara, is a human monoclonal antibody with a unique mechanism of action that has potential in treating Crohn's disease and ulcerative colitis ...